Clinical Characteristics and Treatment Outcomes of Patients with Isoniazid‐Monoresistant Tuberculosis
Clinical Infectious Diseases2008Vol. 48(2), pp. 179–185
Citations Over TimeTop 12% of 2008 papers
Adithya Cattamanchi, Raymund Dantes, John Metcalfe, Leah G. Jarlsberg, Jennifer Grinsdale, L. Masae Kawamura, Dennis Osmond, Philip C. Hopewell, Payam Nahid
Abstract
A history of treatment for latent or active tuberculosis was associated with subsequent INH monoresistance. Treatment outcomes for patients with INH-monoresistant tuberculosis were excellent and were no different from those for patients with drug-susceptible tuberculosis. However, new, short-course regimens are needed because a small proportion of patients completed the 6-month treatment regimen recommended by the American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America, primarily because of pyrazinamide intolerance.
Related Papers
- → Global and Regional Burden of Isoniazid-Resistant Tuberculosis(2015)45 cited
- → Isoniazid in the Prevention and Treatment of Tuberculosis(1974)51 cited
- → Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid(2019)6 cited
- → Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: a case-control study(2019)6 cited
- → Isoniazid-resistant Tuberculosis in Birmingham, 1999–2009(2011)